An Undetectable Pb MRD Status Should Be the Therapeutic Goal With Venetoclax Therapy in Relapsed/ Refractory CLL

Hematological Oncology - United Kingdom
doi 10.1002/hon.70_2629
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Wiley

Related search

Clinical Outcomes From Venetoclax Based Therapy in Patients With Relapsed/Refractory B-Cell Lymphomas

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2019English

Venetoclax: Another Oral Therapy Option for Patients With CLL

Pharmacy Today
2016English

Venetoclax (Ven) in Patients With Relapsed/Refractory Non-Hodgkin Lymphoma (Nhl)

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2017English

Relapsed/Refractory ETP-all Successfully Treated With Novel Combination Therapy Venetoclax With Nelarabine Prior to Allogeneic Stem Cell Transplant

Pathology
Forensic MedicinePathology
2020English

Clinical Experience With the BCL2-inhibitor Venetoclax in Combination Therapy for Relapsed and Refractory Acute Myeloid Leukemia and Related Myeloid Malignancies

American Journal of Hematology
Hematology
2017English

Rescue Therapy for Refractory ARDS Should Be Offered Early: No

Intensive Care Medicine
Critical CareIntensive Care Medicine
2015English

Rescue Therapy for Refractory ARDS Should Be Offered Early: Yes

Intensive Care Medicine
Critical CareIntensive Care Medicine
2015English

Psy81 - Direct Costs Associated With the Treatment of Chronic Lymphocytic Leukemia (Cll) Relapsed or Refractory in Argentina

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Phase Ib/Ii Study of Ibrutinib and Venetoclax in Relapsed and Refractory Follicular Lymphoma

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2019English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy